bpc-157 fda warning not approved peptide safety EVEXIAS Life Sciences filing lawsuit over peptides fda warning bpc-157 unapproved peptide

The rationale for combining BPC-157 and TB-500 stems from their distinct but complementary mechanisms

The OASIS-based DC Function measure will replace the two OASIS-based TNC measures (Self-Care and Mobility)

LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial

Younger patients (ages 2040) dealing with chronic fatigue or exercise intolerance linked to mitochondrial inefficiency

L., Dib, M

For many people, suboptimal B12 levels are a significant and correctable contributing factor